OTCMKTS:CLPBY

Coloplast A/S (CLPBY) Stock Forecast, Price & News

$10.51

0.00 (0.00%)

(As of 09/27/2023 ET)

Compare

Today's Range: $10.44
▼
$10.60
50-Day Range: $10.51
▼
$12.52
52-Week Range: $9.58
▼
$14.77

Volume: 89,350 shs
Average Volume: 51,305 shs
Market Capitalization: $22.70 billion

P/E Ratio: 37.54
Dividend Yield: 0.73%
Price Target: N/A

Profile Analyst Ratings Chart Competitors Dividend Financials Headlines SEC Filings Short Interest

Coloplast A/S MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.00% of Shares Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: -0.33
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 12.50%
From $0.32 to $0.36 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Coloplast A/S.

3.0

Short Interest

Percentage of Shares Shorted
0.00% of the outstanding shares of Coloplast A/S have been sold short.
Short Interest Ratio / Days to Cover
Coloplast A/S has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Coloplast A/S has recently increased by 493.10%, indicating that investor sentiment is decreasing significantly.

2.5

Dividend Strength

Dividend Yield
Coloplast A/S pays a meaningful dividend of 1.40%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Coloplast A/S does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Coloplast A/S is 27.50%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Coloplast A/S will have a dividend payout ratio of 21.39% next year. This indicates that Coloplast A/S will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLPBY.

0.9

News and Social Media Coverage

News Sentiment
Coloplast A/S has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Coloplast A/S this week, compared to 0 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Coloplast A/S insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.10% of the stock of Coloplast A/S is held by institutions.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Coloplast A/S are expected to grow by 12.50% in the coming year, from $0.32 to $0.36 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Coloplast A/S is 37.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.89.
Price to Earnings Ratio vs. Sector
The P/E ratio of Coloplast A/S is 37.54, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.39.
Price to Book Value per Share Ratio
Coloplast A/S has a P/B Ratio of 21.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Coloplast A/S (OTCMKTS:CLPBY) Stock

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

CLPBY Price History

30 days | 90 days | 365 days | Advanced Chart

CLPBY Stock News Headlines

September 23, 2023 | americanbankingnews.com

Coloplast A/S (OTCMKTS:CLPBY) Receives Average Rating of "Hold" from Analysts

September 1, 2023 | finance.yahoo.com

Coloplast A/S - Announcement no. 08/2023 - Coloplast announces registration of share capital increase of 12.2 new B shares completed

September 28, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 18, 2023 | finance.yahoo.com

Major shareholder notification

August 17, 2023 | finance.yahoo.com

Coloplast A/S - Announcement no. 04/2023 - Interim Financial Report, 9M 2022/2023

July 7, 2023 | finance.yahoo.com

Coloplast A/S - Announcement no. 03/2023 - Coloplast announces agreement to acquire Kerecis and raises long-term growth expectations

May 19, 2023 | seekingalpha.com

CLPBY Coloplast A/S

May 13, 2023 | msn.com

Coloplast AS - Class B (CLPBF) Declares $5.00 Dividend

September 28, 2023 | Micro-Cap Stock Trader (Ad)

Unlock the treasure on Mount Olympus with this little-known mining stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

May 11, 2023 | finance.yahoo.com

Coloplast A/S - Announcement no. 02/2023 - Interim Financial Report, H1 2022/23

May 7, 2023 | cbsnews.com

Sam's Club May 2023 membership deal: Get one year of discounted gas, food and more for $35

April 24, 2023 | finance.yahoo.com

New clinical study demonstrates significant improvement in pulmonary health and related symptoms when using Provox® Life™

April 5, 2023 | benzinga.com

Short Volatility Alert: Coloplast

March 28, 2023 | cbsnews.com

Sam's Club March membership deal: Get one year of discounted gas, groceries and more for $25

February 25, 2023 | finance.yahoo.com

Coloplast A/S: Coloplast Introduces Next-Generation Catheter; No Change to Our Fair Value Estimate

November 18, 2022 | finance.yahoo.com

Coloplast Launches New Catheter in the U.S.

November 15, 2022 | finance.yahoo.com

Coloplast appoints new President of its global Interventional Urology business

November 10, 2022 | finance.yahoo.com

Coloplast enters into Power Purchase Agreement with Better Energy

November 8, 2022 | finance.yahoo.com

Coloplast A/S - Announcement no. 12/2022 - Notice of Annual General Meeting

November 7, 2022 | finance.yahoo.com

Coloplast A/S - Announcement no. 10/2022 - Annual Report 2021/22 & Remuneration Report 2021/22

November 7, 2022 | finance.yahoo.com

Coloplast A/S - Announcement no. 11/2022 - Sustainability Report 2021/22

November 7, 2022 | finance.yahoo.com

Coloplast A/S Announcement no. 9/2022 - Full-Year Financial Results 2021/22

October 6, 2022 | finance.yahoo.com

Coloplast launches Saffron™ Fixation System for Prolapse Repair

September 12, 2022 | reuters.com

Coloplast A/S

September 8, 2022 | finance.yahoo.com

Coloplast A/S - Announcement no. 08/2022 - Financial Calendar 2022-23

August 17, 2022 | markets.businessinsider.com

Coloplast A-S (spons ADRs) is about to announce earnings — here's what Wall Street expects

August 17, 2022 | finance.yahoo.com

Coloplast A/S: Coloplast Delivers Strong Fiscal Third Quarter; Our Fair Value Estimate Is Unchanged

See More Headlines

Receive CLPBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coloplast A/S and its competitors with MarketBeat's FREE daily newsletter.

CLPBY Company Calendar

Last Earnings: 5/02/2019
Today: 9/28/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Medical Instruments & Supplies
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:CLPBY
Previous Symbol: NASDAQ:CLPBY
CUSIP: N/A
CIK: 1294325
Web: www.coloplast.com
Phone: (454) 911-1111
Fax: N/A
Employees: 14,700
Year Founded: 1954

Profitability

EPS (Most Recent Fiscal Year): $0.28
Trailing P/E Ratio: 37.54
Forward P/E Ratio: 32.84
P/E Growth: N/A
Net Income: $585.21 million
Net Margins: 21.62%
Pretax Margin: N/A
Return on Equity: 69.30%
Return on Assets: 33.77%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 1.29
Quick Ratio: 0.90

Sales & Book Value

Annual Sales: $2.76 billion
Price / Sales: 8.22
Cash Flow: $0.20 per share
Price / Cash Flow: 52.47
Book Value: $0.48 per share
Price / Book: 21.90

Miscellaneous

Outstanding Shares: 2,160,000,000
Free Float: N/A
Market Cap: $22.70 billion
Optionable: Not Optionable
Beta: 0.28

Social Links

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Kristian Villumsen (Age 53)
Pres & CEO
Comp: $2.24M

Mr. Anders Lonning-Skovgaard (Age 51)
Exec. VP & CFO
Comp: $1.14M

Mr. Allan Rasmussen (Age 56)
Exec. VP of Global Operations
Comp: $1.01M

Mr. Nicolai Buhl Andersen (Age 54)
Exec. VP of Innovation
Comp: $969.63k

Mr. Paul Marcun (Age 56)
Exec. VP of Growth
Comp: $1.16M

Mr. Thomas Barfod (Age 53)
Sr. Controller & Employees Representative Director
Comp: $64.17k

Ellen Bjurgert
VP of Investor Relations

Dennis Kaysen
Director of Corp. Communications

Dorthe Ronnau (Age 57)
Sr. VP of People & Culture

Mr. Alain Morvan
Sr. VP of Sales Europe

Key Competitors

View All Competitors

CLPBY Stock - Frequently Asked Questions

Should I buy or sell Coloplast A/S stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coloplast A/S in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CLPBY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLPBY, but not buy additional shares or sell existing shares.
View CLPBY analyst ratings or view top-rated stocks.
How have CLPBY shares performed in 2023?: Coloplast A/S's stock was trading at $11.63 at the beginning of the year. Since then, CLPBY shares have decreased by 9.6% and is now trading at $10.51.
View the best growth stocks for 2023 here.
Are investors shorting Coloplast A/S?: Coloplast A/S saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 51,600 shares, an increase of 493.1% from the August 31st total of 8,700 shares. Based on an average daily volume of 122,600 shares, the short-interest ratio is presently 0.4 days.
View Coloplast A/S's Short Interest.
How were Coloplast A/S's earnings last quarter?: Coloplast A/S (OTCMKTS:CLPBY) posted its quarterly earnings results on Thursday, May, 2nd. The company reported $0.07 EPS for the quarter, hitting analysts' consensus estimates of $0.07. The company earned $688.45 million during the quarter. Coloplast A/S had a net margin of 21.62% and a trailing twelve-month return on equity of 69.30%.
How often does Coloplast A/S pay dividends? What is the dividend yield for Coloplast A/S?: Coloplast A/S declared a dividend on Wednesday, May 17th. Investors of record on Monday, May 22nd will be paid a dividend of $0.0475 per share on Tuesday, May 30th. This represents a yield of 1.34%. The ex-dividend date of this dividend is Friday, May 19th.
Read our dividend analysis for CLPBY.
Is Coloplast A/S a good dividend stock?: Coloplast A/S (OTCMKTS:CLPBY) pays an annual dividend of $0.08 per share and currently has a dividend yield of 1.40%. The dividend payout ratio is 27.50%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CLPBY will have a dividend payout ratio of 21.39% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CLPBY.

What is Coloplast A/S's stock symbol?: Coloplast A/S trades on the OTCMKTS under the ticker symbol "CLPBY."
How do I buy shares of Coloplast A/S?: Shares of CLPBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Coloplast A/S's stock price today?: One share of CLPBY stock can currently be purchased for approximately $10.51.
How much money does Coloplast A/S make?: Coloplast A/S (OTCMKTS:CLPBY) has a market capitalization of $22.70 billion and generates $2.76 billion in revenue each year. The company earns $585.21 million in net income (profit) each year or $0.28 on an earnings per share basis.
How many employees does Coloplast A/S have?: The company employs 14,700 workers across the globe.
How can I contact Coloplast A/S?: Coloplast A/S's mailing address is HOLTEDAM 1-3, HUMLEBAEK G7, 3050. The official website for the company is www.coloplast.com. The company can be reached via phone at (454) 911-1111 or via email at dkebj@coloplast.com.

This page (OTCMKTS:CLPBY) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Coloplast A/S (CLPBY) Stock Forecast, Price & News

Coloplast A/S MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Coloplast A/S (OTCMKTS:CLPBY) Stock

CLPBY Price History

CLPBY Stock News Headlines

CLPBY Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

CLPBY Stock - Frequently Asked Questions

Overall MarketRank^™